- /
- Supported exchanges
- / US
- / NONOF.PINK
Novo Nordisk A/S (NONOF PINK) stock market data APIs
Novo Nordisk A/S Financial Data Overview
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin dose guidance application; and growth hormone pens and injection needles. It operates in Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong and Taiwan, Latin America, the Middle East, and Africa. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Novo Nordisk A/S (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Novo Nordisk A/S data using free add-ons & libraries
Get Novo Nordisk A/S Fundamental Data
Novo Nordisk A/S Fundamental data includes:
- Net Revenue: 327 800 M
- EBITDA: 173 876 M
- Earnings Per Share: 4
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-05-06
- EPS/Forecast: 5.46
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Novo Nordisk A/S News
New
Lilly weight-loss pill prescriptions said to have exceeded 7,000 in fourth week
[Indianapolis - April 2016: Eli Lilly and Company VII] jetcityimage/iStock Editorial via Getty Images U.S. prescriptions for Eli Lilly’s (LLY [https://seekingalpha.com/symbol/LLY]) new obesity pill...
European Stocks Decline in Friday Trading; Middle East Ceasefire Tenuous Amid Rising US-Iran Tensions
The European stock markets were tracking lower, and oil prices were rising Friday following media re PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscri...
Prothena Posts Q1 Earnings as Revenues Surge on Milestone Payment
Prothena Corporation PRTA reported first-quarter 2026 adjusted earnings per share (excluding restructuring costs) of 52 cents. The Zacks Consensus Estimate was a loss of 31 cents per share. In the ye...
Novo Nordisk India Sales Jump 40% As Generic Pressure Builds
This article first appeared on GuruFocus. Novo Nordisk A/S (NYSE:NVO) may have just delivered an early warning shot in India's fast-moving obesity-drug market. Instead of watching demand buckle under...
Corporate Events Calendar & News package for
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.